Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: L04AX05

Esbriet(Pirfenidone)

Idiopathic Pulmonary Fibrosis;Lung Diseases;Respiratory Tract Diseases

Marketing Authorisation Holder: H.A.C. Pharma

EMA Authorisation: 28/02/2011

INN: pirfenidone

Indication

Esbriet is indicated in adults for the treatment of idiopathic pulmonary fibrosis.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Esbriet — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.